The launch date of Erlotinib in China

Erlotinib (Erlotinib) is a small molecule tyrosine kinase inhibitor, a classic EGFR-targeted drug, which plays an important role in the treatment of non-small cell lung cancer (NSCLC). It inhibits the activation of epidermal growth factor receptor (EGFR), blocks downstream signaling pathways, and reduces tumor cell proliferation, thereby achieving the purpose of delaying disease progression. Since the proportion of EGFR mutant lung cancer is relatively high in Asian populations, this type of drug has widespread application demand among Chinese patients.

From the perspective of time on the market, the development and promotion of erlotinib was relatively early. The U.S. Food and Drug Administration (FDA) approved its marketing in November 2004 under the trade name Tarceva. It was initially used for patients with non-small cell lung cancer who had previously received chemotherapy. Then in September 2005, the European Medicines Agency (EMA) also approved its application. China's State Food and Drug Administration (formerly SFDA) approved the import registration of the original drug erlotinib in April 2006, with the trade name "Tarceva". This time point means that erlotinib has become one of the earliest EGFR-targeted drugs to be launched in China, bringing new treatment options to the majority of patients.

In clinical practice, the launch of erlotinib not only enriches the treatment options for lung cancer, but also provides impetus for the promotion of molecular classification diagnosis. Its success has made targeted therapy an important research direction for non-small cell lung cancer and promoted the popularization of precision medicine in the country. With the accumulation of drug applications, erlotinib has gradually gained attention in some pancreatic cancer indications, but its core value is still focused on the treatment of lung cancer with EGFR mutations.

At present, erlotinib has been used in China for more than ten years, and the market competition pattern has gradually formed. With the successive launch of generic drugs, patients have more channels to choose from and prices are becoming more reasonable. Although multiple generations of EGFR inhibitors have been subsequently released, erlotinib, as an earlier generation drug, still plays an irreplaceable role in some patient groups.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib